Conv. Plasma
Nigella Sativa

All ursodeoxycholic acid..
Meta analysis
study COVID-19 treatment researchUDCAUDCA (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Recovery time >7 days 48% Improvement Relative Risk Case 83% UDCA for COVID-19  Cui et al.  Prophylaxis Is prophylaxis with ursodeoxycholic acid beneficial for COVID-19? PSM retrospective 215 patients in China Faster recovery (p=0.0096) and fewer cases (p=0.001) Cui et al., J. Clinical Hepatology, Mar 2024 Favors ursodeoxycholic acid Favors control

Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B

Cui et al., Journal of Clinical Hepatology, doi:10.12449/JCH240309
Mar 2024  
  Source   PDF   All   Meta
Retrospective 215 patients with chronic hepatitis B in China, showing lower risk of COVID-19 infection, milder symptoms, and faster recovery with ursodeoxycholic acid (UDCA) treatment.
recovery time >7 days, 47.8% lower, RR 0.52, p = 0.010, treatment 13 of 64 (20.3%), control 51 of 131 (38.9%), NNT 5.4, propensity score matching.
risk of case, 83.0% lower, OR 0.17, p = 0.001, treatment 78, control 137, adjusted per study, propensity score matching, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cui et al., 20 Mar 2024, retrospective, China, peer-reviewed, 5 authors.
This PaperUDCAAll
, 缩短恢复时间, 在防治 COVID-19 方面具有重要价值。 关键词: 乙型肝炎, 慢性; 新型冠状病毒; 熊去氧胆酸; 倾向性评分 基金项目: 北京市自然科学基金(7212053) Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B
Cui Xinyu, , Li, , Zhu, , Lin
摘要: 目的 探讨慢性乙型肝炎患者服用熊去氧胆酸后对新型冠状病毒感染
Bergwerk, Gonen, Lustig, Covid-19 breakthrough infections in vaccinated health care workers, J]. N Engl J Med, doi:10.1056/NEJMoa2109072
Beuers U, Trauner, Jansen, New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and be• yond[J], J Hepatol, doi:10.1016/j.jhep.2015.02.023
Brevini, Maes, Gj, FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2[J], Nature, doi:10.1038/s41586-022-05594-0
Chen Yc, Huang Wx, Expert consensus on the application of azvu• dine in the treatment of SARS-CoV-2 infection, J]. China Pharm, doi:10.3969/j.issn.1006-4931.2023.03.001
Davies, Morden, Rosseau, Outcomes of laboratoryconfirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa[J], Int J Infect Dis, doi:10.1016/j.ijid.2022.11.024
Fuchs Cd, Trauner, Role of bile acids and their receptors in gas• trointestinal and hepatic pathophysiology[J], Nat Rev Gastroenterol Hepatol, doi:10.1038/s41575-021-00566-7
Garg, Hospitalization rates and charac• teristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 States
Gaziano, Giambartolomei, Pereira Ac, Actionable druggable genome-wide Mendelian randomization identifies repur• posing opportunities for COVID-19, J]. Nat Med, doi:10.1038/s41591-021-01310-z
Levin Eg, Lustig, Cohen, Waning immune humoral re• sponse to BNT162b2 Covid-19 vaccine over 6 months, J]. N Engl J Med, doi:10.1056/NEJMoa2114583
Li Q, Guan, Wu, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J], N Engl J Med, doi:10.1056/NEJMoa2001316
Li Yg, Zh, Efficacy of tenofovir combined with ursodeoxycholic acid in outpatient treatment of chronic hepatitis B[J], Health Med Res Prac, doi:10.11986/j.issn.1673-873X.2022.04.006
Li, Therapeutic options for the 2019 novel coronavi• rus (2019-nCoV) [J], Nat Rev Drug Discov, doi:10.1038/d41573-020-00016-0
Liu, Feng, Ren, The influencing factors of abnormal liver function in patients with COVID-19 and its dynamic changes in different drug treatments[J], J Capit Med Univ, doi:10.3969/j.issn.1006-7795.2022.03.017
Reiffel, Propensity score matching: The 'devil is in the details' where more may be hidden than you know[J], Am J Med, doi:10.1016/j.amjmed.2019.08.055
Sj, Treatment of chronic hepatitis B focuses on improving disease resistance[J], Guangming J Chin Med, doi:10.3969/j.issn.1003-8914.2012.08.003
Sl, Yt, Cai Xj, Research progress on anticoro• navirus drugs[J], Chin J Comp Med, doi:10.3969/j.issn.1671-7856.2022.06.016
Sun Xl, Hu, Yt, Clinical application of ursodeoxycholic acid [J], Chin J Pharmacov, doi:10.19803/j.1672-8629.20210604
Sy, Peng, Xh, Pathogenic mechanism of liver injury caused by coronavirus disease 2019 and protective strategies for pa• tients with viral hepatitis cirrhosis[J], J Clin Hepatol, doi:10.3969/j.issn.1001-5256.2020.07.037
Van Den Bossche L, Hindryckx, Devisscher, Urso• deoxycholic acid and its taurine-or glycine-conjugated species re• duce colitogenic dysbiosis and equally suppress experimental coli• tis in mice[J], Appl Environ Microbiol, doi:10.1128/AEM.02766-16
Verity R, Lc, Dorigatti, Estimates of the severity of coronavirus disease 2019: a model-based analysis, J]. Lancet Infect Dis, doi:10.1016/S1473-3099(20)30243-7
Wang Ch, Yao, Wang R, The latest research progress of novel coronavirus "Omicron sub-variant BA. 5, J Hanan Med Coll, doi:10.13210/j.cnki.jhmu.20220909.002
Wang Q, Guo, Iketani, Antibody evasion by SARS-CoV-2 Omicron subvariants BA, BA.4 and BA, doi:10.1038/s41586-022-05053-w
Who, Weekly epidemiological update on COVID-19 -22
Xy, Yy, Zhu, Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B[J], J Clin Hepatol
Yang, Xu, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study[J], Lancet Respir Med, doi:10.1016/S2213-2600(20)30079-5
Ye, Sw, Clinical evaluation of taurine ursodeoxycholic acid in the treatment of chronic hepatitis B with overlapping hepatitis E infec• tion[J], Chin Foreign Med Res, doi:10.14033/j.cnki.cfmr.2019.08.022
Zampino R, Mele, Ll, Liver injury in remdesivirtreated COVID-19 patients, J]. Hepatol Int, doi:10.1007/s12072-020-10077-3
Zhang, Xuqing: Can patients with liver disease be vacci• nated with COVID-19 vaccine?, J]. Liver Doctor
崔心宇, 朱娜, 效 果 分 []. 临 床 肝 胆 病 杂 志
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop